Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Preferred Dividend Payments (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Preferred Dividend Payments for 13 consecutive years, with $24000.0 as the latest value for Q4 2025.

  • Quarterly Preferred Dividend Payments fell 50.0% to $24000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $148000.0 through Dec 2025, down 14.94% year-over-year, with the annual reading at $150000.0 for FY2025, 13.79% down from the prior year.
  • Preferred Dividend Payments hit $24000.0 in Q4 2025 for Guided Therapeutics, down from $43000.0 in the prior quarter.
  • In the past five years, Preferred Dividend Payments ranged from a high of $548000.0 in Q1 2022 to a low of -$55000.0 in Q1 2021.
  • Historically, Preferred Dividend Payments has averaged $73700.0 across 5 years, with a median of $47500.0 in 2022.
  • Biggest five-year swings in Preferred Dividend Payments: tumbled 558.33% in 2021 and later skyrocketed 1096.36% in 2022.
  • Year by year, Preferred Dividend Payments stood at $65000.0 in 2021, then dropped by 23.08% to $50000.0 in 2022, then fell by 2.0% to $49000.0 in 2023, then fell by 2.04% to $48000.0 in 2024, then plummeted by 50.0% to $24000.0 in 2025.
  • Business Quant data shows Preferred Dividend Payments for GTHP at $24000.0 in Q4 2025, $43000.0 in Q3 2025, and $45000.0 in Q2 2025.